|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||456.469 g·mol−1|
|3D model (JSmol)|
PF-3845 is a selective inhibitor of fatty acid amide hydrolase. It results in increased levels of anandamide and results in cannabinoid receptor-based effects. It has anti-inflammatory action in mice colitis models. Antidiarrheal and antinociceptive effects were also seen in mouse models of pain.
A 2017 study published in the Journal of Psychiatry and Neuroscience found that PF-3845 exerts rapid and long-lasting anti-anxiety effects in mice exposed acutely to stress or chronically to the stress hormone corticosterone.
- Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, et al. (April 2009). "Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain". Chemistry & Biology. 16 (4): 411–20. doi:10.1016/j.chembiol.2009.02.013. PMC 2692831. PMID 19389627.
- Fichna J, Sałaga M, Stuart J, Saur D, Sobczak M, Zatorski H, et al. (April 2014). "Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides". Neurogastroenterology and Motility. 26 (4): 470–81. doi:10.1111/nmo.12272. PMID 24460851.
- Duan T, Gu N, Wang Y, Wang F, Zhu J, Fang Y, et al. (June 2017). "Fatty acid amide hydrolase inhibitors produce rapid anti-anxiety responses through amygdala long-term depression in male rodents". Journal of Psychiatry & Neuroscience. 42 (4): 230–241. doi:10.1503/jpn.160116. PMC 5487270. PMID 28234213.